← Leaderboards
Philip L De Jager
Columbia University Health Sciences
$51,471,411
Attributed
$87,902,194
Total exposure
23
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $15.4M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$106,956,735 · 24
By mechanism
U01$47,010,474 · 4
U19$27,270,693 · 7
RF1$19,761,346 · 4
R01$7,533,533 · 4
RC2$2,654,871 · 1
P30$1,087,883 · 2
Top collaborators
- David A Bennett23 shared
- Eric A Boerwinkle8 shared
- Anita L Destefano8 shared
- Myriam Fornage8 shared
- Sudha Seshadri8 shared
- Ellen M Wijsman8 shared
- Peter Henry St George-Hyslop6 shared
- Vilas Menon3 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Peter Henry St George-Hyslop$4,779,070
- Tal Nuriel$6,961,826
- Elizabeth M Bradshaw$11,004,520
- Wassim Elyaman$6,169,565
- David Dominguez-Sola$4,189,942
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseGenesMolecularBrainCellsImpaired CognitionAgingSamplingProgramsPathologyProteinsData SetResourcesValidationGenerationsParticipantDementiaTranscriptomicsTissuesCell TypeMapsGeneticVariant
Grant awards (82)
Defining the effect of Alzheimer pathologies on the aged brain in 3 dimensions$6,207,555
U19 · FY2025 · AG · contact PI
Alzheimer variants: Propagation of shared functional changes across cellular networks$1,556,403
U01 · FY2025 · AG · contact PI
Project 4: Integrative analysis of spatial molecular features and clinico-pathological characteristics$1,349,606
U19 · FY2025 · AG · contact PI
Project 3: 3-D Molecular Atlas of cerebral amyloid angiopathy in the aging brain with and without co-pathology$680,702
U19 · FY2025 · AG · contact PI
Core A: Administrative Core$617,338
U19 · FY2025 · AG · contact PI
Core B: Biospecimen Core$248,695
U19 · FY2025 · AG · contact PI
Neuroimmunology Core$189,175
P30 · FY2025 · AG · contact PI
Defining the effect of Alzheimer pathologies on the aged brain in 3 dimensions$6,328,789
U19 · FY2024 · AG · contact PI
Alzheimer variants: Propagation of shared functional changes across cellular networks$1,607,103
U01 · FY2024 · AG · contact PI
Project 4: Integrative analysis of spatial molecular features and clinico-pathological characteristics$1,591,238
U19 · FY2024 · AG · contact PI
Discovery and validation of genetic variants affecting microglial activation in Alzheimer's disease$1,572,761
R01 · FY2024 · AG · contact PI
Core A: Administrative Core$625,518
U19 · FY2024 · AG · contact PI
Alzheimer variants: Propagation of shared functional changes across cellular networks$432,310
U01 · FY2024 · AG · contact PI
Neuroimmunology Core$176,063
P30 · FY2024 · AG · contact PI
Defining the effect of Alzheimer pathologies on the aged brain in 3 dimensions$6,518,197
U19 · FY2023 · AG · contact PI
Alzheimer variants: Propagation of shared functional changes across cellular networks$1,645,118
U01 · FY2023 · AG · contact PI
Project 4: Integrative analysis of spatial molecular features and clinico-pathological characteristics$1,602,525
U19 · FY2023 · AG · contact PI
Core A: Administrative Core$670,902
U19 · FY2023 · AG · contact PI
Targeted in vivo perturbation for dissecting tissue immune responses$280,366
U19 · FY2023 · AI · contact PI
Neuroimmunology Core$179,237
P30 · FY2023 · AG · contact PI
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets$2,728,790
U01 · FY2022 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$2,147,504
U01 · FY2022 · AG
Alzheimer variants: Propagation of shared functional changes across cellular networks$1,625,206
U01 · FY2022 · AG · contact PI
Integration of immune cell subtypes across diseases & tissue$405,000
U01 · FY2022 · AG · contact PI
Targeted in vivo perturbation for dissecting tissue immune responses$292,943
U19 · FY2022 · AI · contact PI
Neuroimmunology Core$180,826
P30 · FY2022 · AG · contact PI
A shared foundation for single genetic investigations of immune responses$155,483
U01 · FY2022 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$32,137
U01 · FY2022 · AG
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets$2,242,312
U01 · FY2021 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$2,153,560
U01 · FY2021 · AG
Alzheimer variants: Propagation of shared functional changes across cellular networks$1,676,096
U01 · FY2021 · AG · contact PI
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets$416,605
U01 · FY2021 · AG · contact PI
Neuroimmunology Core$176,282
P30 · FY2021 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$128,552
U01 · FY2021 · AG
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$112,663
U01 · FY2021 · AG
Discovery and validation of genetic variants affecting microglial activation in Alzheimer's disease$6,213,164
RF1 · FY2020 · AG · contact PI
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets$3,049,965
U01 · FY2020 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$2,158,021
U01 · FY2020 · AG
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets$1,215,000
U01 · FY2020 · AG · contact PI
Neuroimmunology Core$186,300
P30 · FY2020 · AG · contact PI
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets$181,181
U01 · FY2020 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$2,164,820
U01 · FY2019 · AG
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets$1,648,575
U01 · FY2019 · AG · contact PI
Creating a human microglial sample resource for the Alzheimer's Disease community$385,701
P50 · FY2019 · AG · contact PI
Creating a human microglial sample resource for the Alzheimer's Disease community$376,370
P50 · FY2019 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$2,233,154
U01 · FY2018 · AG
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets$1,668,072
U01 · FY2018 · AG · contact PI
Deconstructing and modeling the single cell architecture of the Alzheimer brain$405,000
RF1 · FY2018 · AG · contact PI
Identifying, validating and targeting AD susceptibility networks in monocytes$394,988
R01 · FY2018 · AG · contact PI
Deconstructing and modeling the single cell architecture of the Alzheimer brain$3,591,103
RF1 · FY2017 · AG · contact PI
Pathway discovery, validation and compound identification for Alzheimer's disease$2,032,810
U01 · FY2017 · AG · contact PI
Identifying, validating and targeting AD susceptibility networks in monocytes$367,990
R01 · FY2017 · AG · contact PI
Pathway discovery, validation and compound identification for Alzheimer's disease - Supplement$156,336
U01 · FY2017 · AG · contact PI
Exploring the Role of the Brain Epigenome: Cognitive Decline and Life Experiences$5,523,657
RF1 · FY2016 · AG
Demystifying Microglia in Aging and Alzheimer's Disease$4,028,422
RF1 · FY2016 · AG
Pathway discovery, validation and compound identification for Alzheimer's disease$3,789,650
U01 · FY2016 · AG · contact PI
Pathway discovery, validation and compound identification for Alzheimer's disease$1,572,897
U01 · FY2016 · AG · contact PI
Identifying, validating and targeting AD susceptibility networks in monocytes$367,990
R01 · FY2016 · AG · contact PI
Pathway discovery, validation and compound identification for Alzheimer's disease$153,950
U01 · FY2016 · AG · contact PI
Pathway discovery, validation and compound identification for Alzheimer's disease$2,162,184
U01 · FY2015 · AG · contact PI
Identifying, validating and targeting AD susceptibility networks in monocytes$386,375
R01 · FY2015 · AG · contact PI
Pathway discovery, validation and compound identification for Alzheimer's disease$178,752
U01 · FY2015 · AG · contact PI
Pathway discovery, validation and compound identification for Alzheimer's disease$1,771,130
U01 · FY2014 · AG · contact PI
Exploring the Role of the Brain Transcriptome in Cognitive Decline$725,828
R01 · FY2014 · AG · contact PI
Identifying, validating and targeting AD susceptibility networks in monocytes$357,795
R01 · FY2014 · AG · contact PI
Pathway discovery, validation and compound identification for Alzheimer's disease$114,934
U01 · FY2014 · AG · contact PI
Pathway discovery, validation and compound identification for Alzheimer's disease$1,694,201
U01 · FY2013 · AG · contact PI
Exploring the Role of the Brain Transcriptome in Cognitive Decline$732,100
R01 · FY2013 · AG · contact PI
Exploring the Role of the Brain Transcriptome in Cognitive Decline$784,740
R01 · FY2012 · AG · contact PI
Data Repository and Curation$3,259
U19 · FY2012 · AI · contact PI
Exploring the Role of the Brain Transcriptome in Cognitive Decline$685,904
R01 · FY2011 · AG · contact PI
Exploring the consequences of the TNFRSF1A susceptibility allele for MS$382,570
R01 · FY2011 · NS · contact PI
Data Repository and Curation$253,060
U19 · FY2011 · AI · contact PI
Genome-Wide Association Study of Cognitive Decline Among Older African Americans$1,321,004
RC2 · FY2010 · AG
Exploring the consequences of the TNFRSF1A susceptibility allele for MS$385,482
R01 · FY2010 · NS · contact PI
Genome-Wide Association Study of Cognitive Decline Among Older African Americans$1,333,867
RC2 · FY2009 · AG
Exploring the consequences of the TNFRSF1A susceptibility allele for MS$389,010
R01 · FY2009 · NS · contact PI
Exploration of the Genetic Basis of Multiple Sclerosis$175,176
K08 · FY2007 · NS · contact PI
Exploration of the Genetic Basis of Multiple Sclerosis$175,176
K08 · FY2006 · NS · contact PI
Exploration of the Genetic Basis of Multiple Sclerosis$175,160
K08 · FY2005 · NS
Exploration of the Genetic Basis of Multiple Sclerosis$175,176
K08 · FY2004 · NS
Exploration of the Genetic Basis of Multiple Sclerosis$175,176
K08 · FY2003 · NS